These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Gastrointestinal side effects of apremilast : Characterization and management].
    Author: Pinter A, Beigel F, Körber A, Homey B, Beissert S, Gerdes S, Staubach-Renz P, Radtke MA, Mössner R.
    Journal: Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481.
    Abstract:
    Apremilast is an oral inhibitor of phosphodiesterase-4 (PDE4) that is licensed for the second-line treatment of psoriasis and psoriatic arthritis. Data from several phase III clinical trials and real-world studies showed a good benefit-risk profile, with diarrhea and nausea as the most common adverse events. Diarrhea and nausea most frequently occurred during the first month of treatment. In most cases, they were mild or moderate in severity and tended to resolve over time with continued dosing and without intervention. In this review we summarize available data on gastrointestinal side effects of apremilast in patients with psoriasis and psoriasis arthritis and provide practical strategies for managing these symptoms.
    [Abstract] [Full Text] [Related] [New Search]